Logie. Int J Cancer. 2001, 94:185 191st Emlet DR, Schwartz R, Brown KA, AA Pollice, CA Smith, Shackney SE. HER2 expression LY335979 Zosuquidar as a potential marker for the response to the specific treatment of EGFR. Br J Cancer. 2006, 94:1144 1153rd Faltus T, Yuan J, Hall B, Kramer A, S Loibl, Kaufmann M, et al. The silent HER2/neu gene by siRNA age inhibits proliferation and induces apoptosis in the cells overexpressing HER2/neu breast cancer. Neoplasia. 2004 795. Finn RS 6:786, CA Wilson, J. Chen, Glaspy P, Dering J, Koch A, Yang E, Sanders J, Britten C, Slamon DJ. The biological effects of CP 724714, a selective inhibitor of the kinase HER-2/neu second SA on human breast cancer cells with variable expression of EGFR and HER Proc Am Assoc Can Res 2004 Jan 3.
45 G # 4556th Fleming, Gordon MS, Matei D, Aghajanian C, Matulonis UA, MA Brewer, Fleming, Hainsworth JD, Garcia AA, Pegram M, Karlan BY. The clinical efficacy of pertuzumab in advanced ovarian cancer refractory Rer or recurrent Rer r and HER2 status of the activation. Proc Amer Soc Clin Onc. 2005, 23 # 5051st Fleming GF, Sill MA, Thigpen Raltitrexed JT, Adler LM, Berek JS, DiSilvestro PA, Horowitz IR. Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial cancer: a report on GOG 181B. Proc Amer Soc Clin Onc. 2003, 22 # 1821st Friess T, Scheuer W, Combination treatment with erlotinib and pertuzumab Hasmann Mr gr He human than monotherapy tumor xenografts. Clin Cancer Res 2005, 11:5300 5309th Fujii A, Suzuki T, Ohya JI, Nakamura H, Fujita M, Koike M, et al. MP 412, a dual EGFR/HER2 tyrosine kinase second Anti-tumor effect in vivo.
Proc Am Assoc Can Res 2005, 46 # 3394th Page 15 Moasser Oncogene. Author manuscript 6th, April 2011 PMC. Fujita T, Doihara H, K Kawasaki, Takabatake D, Takahashi H, Washio K., et al. PTEN activity t Tk Nnte pr Diktiven a marker for the efficacy of trastuzumab for the treatment of breast cancer overexpressing HER2 be. Br J Cancer. 2006 Garrett TP, McKern NM, Lou M, Elleman TC, TE Adams, GO Lovrecz, et al. The crystal structure of a truncated ErbB2 you Ektodom reveals an active conformation, ready to interact with other ErbB receptors. Mol Cell. 2003, 11:495 505th Gennari R, Menard S, F Fagnoni, Ponchio L, Scelsi M Tagliabue E, et al. Pilot study of the mechanism of action of trastuzumab Operational pr patients with operable primary Ren breast tumors overexpressed HER2 Rer.
Clin Cancer Res 2004, 10:5650 5655th Ghossein RA, S. Bhattacharya. Detection and molecular characterization of circulating tumor cells and micrometastases in prostate, kidney and urothelial Seminars in Surgical Oncology. 2001, 20:304 311th Gomez HL, Chavez MA, Doval DC, Nag S, Chow LW, Ang PC, Ahmad NM, Berger M, B Newstat, Pierre S, Sledge GW. Biomarker results of the randomized phase II lapatinib as first-line treatment for patients with advanced cancer HER2 FISH versts RKT or metastatic breast cancer. Breast Cancer Res Treat. 2005, 94 Suppl 1: S63. Harwerth IM, Wels W, Marte BM, Hynes NE. Monoclonal Body against the extracellular Re Dom Cathedral directed ne Re function as ligands of erbB receptor partial agonist both. J Biol Chem 1992, 267:15160 15167. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Of monoclonal Rpern against erbB receptor 2 rpern guided inhibit tumor growth in vivo in the cell. Br J Cancer. 1993, 68: